Food and Drug Administration (FDA)
NEWS
The standard physician sample pack of Allergan’s Taytulla birth control pills should have 24 pink capsules that contain hormones with four maroon capsules at the end of the package cycle that do not have hormones. However, 170,000 packages had four maroon placebos located at the beginning of the treatment cycle.
AstraZeneca’s add-on asthma treatment Fasenra has failed a second Phase III trial this month.
Florida-based TherapeuticsMD is feeling a bit vindicated this morning after the U.S. Food and Drug Administration approved its vaginal pain medication.
Since 2009 May 30 has been set aside as a day to raise awareness and campaign for an end to multiple sclerosis. The theme this year is focused on the research being conducted to develop a cure for the neurological disease.
Within the next six years, the multiple myeloma market is projected to be $37.5 billion – an incredible growth of $30 billion since 2015, when the market was valued at about $7.5 billion.
Pfizer’s Xalkori, the first drug approved in the United States for patients with ALK-positive and ROS1-positive non-small cell lung cancer, secured Breakthrough Therapy Designation from the U.S. Food and Drug Administration for two new indications.
Following the long holiday weekend, three pharma companies began the week with good news as the U.S. Food and Drug Administration awarded their therapies with Priority Review Status.
A combination of Genentech’s Tecentriq and chemotherapy enabled some lung cancer patients in a Phase III trial to live significantly longer than chemotherapy alone. The latest report continues the string of successes the company has had with Tecentriq, an anti-PD-L1 immunotherapy.
The Memorial Day Holiday is making the U.S. Food and Drug Administration (FDA)’s schedule a bit more complicated. Here’s a look at two more FDA decisions coming up this week.
JOBS
IN THE PRESS